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doi:10.1016/j.jfma.2012.03.010Background/Purpose: Unique barrier properties of the urothelial surface membrane permit ur-
ine storage without contents leak into the bloodstream. Previous reports suggested that the
bladder urothelial barrier might be compromised in interstitial cystitis/painful bladder
syndrome (IC/PBS). We examined the changes of tight junction proteins (zonula occludens-1
(ZO-1) and occludin) in IC/PBS patients.
Methods: Bladder samples were derived from of 32 patients with IC/PBS and eight controls. We
detected the tight junction proteins of ZO-1 and occludin expression by immunoblotting,
immunohistochemical (IHC) staining and double immunofluorescent (IF) staining with confocal
microscopy. Data were analyzed using the Mann-Whitney U-test.
Results: Expression of ZO-1 and occludin in the IC/PBS group was reduced compared to the
control group by immunoblotting and IHC staining. Also, the thinning and denudation of ur-
othelium were demonstrated in the IC/PBS group by histological study. IF staining showed
the interruption of bladder urothelium in IC/PBS patients under confocal microscopy.
Conclusion: Ourdata showedthatdecreasedexpressionof tight junctionproteins (ZO-1andocclu-
din) and interruption of bladder urothelium in IC/PBS patients. Treatment to repair the discontin-
uous urothelium may be useful to relieve some clinical symptoms of patients with IC/PBS.
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tion 1:100); (3) occludin: a rabbit polyclonal antibody forIn interstitial cystitis/painful bladder syndrome (IC/PBS),
current theories of pathogenesis include a chronic or
subclinical infection, autoimmunity, neurogenic inflamma-
tion or bladder urothelial defects.1 The discontinuous or
disruption of bladder urothelium with leaky tight junctions
leads to the migration of urinary solutes, in particular
potassium, that depolarizes nerve and muscles and cause
tissue injury then resulting in patients with bladder pain,
urgency, and frequency in urination.1,2 The molecular
mechanisms underlying this disease are not well known.
In mammals, the umbrella cells have the tight junctions
that in epithelial cells regulate the movement of ions and
solutes between adjacent cells and prevent molecules
cannot leak freely across the urothelium. The urothelial
barrier function is supported by the structural integrity of
tight junction.2 The tight junction-associated proteins
zonula occludens-1 (ZO-1) and occludin to make up a high-
resistance barrier in the bladder epithelium.1e3
So we examined the tight junction proteins (ZO-1 and
occludin) involved with bladder impermeability in biopsies
from patients with IC/PBS and controls by immunoblotting,
immunohistochemical (IHC) staining and immunofluores-
cent (IF) staining. The present study may provide the
treatment mechanisms for mucosal repair and decreasing
the urothelial permeability to improve patient’s clinical
symptoms.Materials and methods
Patients and tissue samples
Bladder specimens were obtained from 32 patients (26
women and six men) with IC/PBS who were undergoing
cystoscopy under anesthesia for diagnosis or therapeutic
bladder distention. Patients met the cystoscopic criteria
established by the National Institute of Diabetes, Diges-
tive and Kidney Diseases,4 including moderate to severe
disease symptoms of greater than 6 months duration, and
had an average age of 39.4 years (range: 20e55 years). In
the study group, a cold-cup biopsy was taken after
bladder hydrodistention. Control specimens were ob-
tained from 8 patients (median age: 43.7 years, range:
38e47 years; six women and two men) undergoing
a bladder neck suspension procedure for stress urinary
incontinence, who showed no evidence of IC/PBS or
bladder mucosal disease. All tissues were stored at e80C
for immunoblotting or fixed in formalin for immunostain-
ing. All specimens were removed only after obtaining
informed written consent from the patients. This study
was approved by the Institutional Review Board of Tri-
Service General Hospital.
Antibodies
Five primary antibodies were used in the present study:
(1,2) ZO-1: a rabbit polyclonal antibody for immunoblotting
and IHC staining (sc-10804, Santa Cruz, CA, USA; dilution
1:400) and a mouse monoclonal antibody for whole mountIF staining (#33-9100, Invitrogen, Camarillo, CA, USA; dilu-
immunoblotting, IHC and whole mount IF staining (#71-
1500, Invitrogen; dilution 1: 500 and 1:100 for immuno-
blotting and immunostaining, respectively); (4) CK7 (cyto-
keratin 7): a mouse monoclonal antibody (NCL-L-CK7-OVTL,
Novocastra, UK; dilution 1:500) for IHC staining; and (5) b-
actin: a mouse monoclonal antibody (#8226, Abcam, Cam-
bridge, MA, USA; dilution 1:8000) for immunoblotting.
The secondary antibodies for immunoblotting were
horseradish peroxidase (HRP)-conjugated goat anti-mouse
IgG (#0031430, Pierce, Hercules, CA, USA) or goat anti-
rabbit IgG (#0031460, Pierce). The secondary antibodies for
immunostaining were the commercial kit (PicTure; Zymed,
South San Francisco, CA, USA) for IHC staining and the
Alexa-Fluor 488 conjugated goat anti-rabbit (Molecular
Probes, Eugene, OR, USA; dilution 1:50) or the Alexa Fluor
546 conjugated goat anti-mouse antibodies (Molecular
Probes; dilution 1:200) for whole mount IF staining.
Preliminary experiments of negative controls (samples
stained with only primary or secondary antibodies)
demonstrated that either non-specific staining or over-
staining of the background was not found (data not shown)
in whole mount IF staining.
Immunoblotting
The method used was modified from our previous studies.5,6
After homogenizing and centrifuging, the supernatants
were used for determination of protein concentrations or
immunoblotting. Protein concentrations were identified by
reagents from BCA Protein Assay Kit (#23225, Pierce,
Hercules, CA, U.S.A.), using bovine serum albumin (BSA) as
a standard (#23209, Pierce).
For immunoblotting, the antibodies of ZO-1, occludin
and b-actin (loading control) revealed molecular weights of
about 220, 65 and 42 kDa, respectively. The blots were cut
into upper and lower portions at feasible sites for incuba-
tion, incubated at 4C overnight with the diluted primary
antibodies, and then incubated with diluted secondary
antibody for 1 hour. Finally, the immunoreactive bands
were analyzed by using MCID software version 7.0 (Imaging
Research, Ontario, Canada). The results were converted to
numerical values in order to compare the relative protein
abundance of the immunoreactive bands.
Immunohistochemistry
The method of staining and microscopy were modified from
our previous studies.5,7 In brief, the formalin-fixed and
paraffin-embedded sections (4 mm) of samples were dew-
axed, and then they were rinsed by phosphate buffered
saline. The sections were stained with the primary antibody
(CK7, ZO-1, or occludin) before being analyzed with the
commercial kit. Negative control experiments, in which
phosphate buffered saline was used instead of the primary
antibody, were conducted to confirm the positive results of
CK7, ZO-1, or occludin (data not shown). Finally, the
sections were counterstained with hematoxylin (Cat.
No.1.05175.0500, Merck, Darmstadt, Germany) and rinsed
by tap water. Sections were observed using a light
Figure 1 Representative immunoblot and relative intensities
of ZO-1 protein in study and control groups. b-actin was used as
loading control. The asterisk indicates a significant difference
(p < 0.05). ZO-1 Z zonula occludens-1.
Figure 2 Representative immunoblot and relative intensities
of occludin protein in study and control groups. b-actin was
used as loading control. The asterisk indicates a significant
difference (p < 0.05).
ZO-1 and occludin in IC/PBS bladder urothelium. 19microscope (BX50, Olympus, Tokyo, Japan) and the micro-
graphs were pictured.
Whole mount double immunofluorescent staining
and confocal microscopy
The method used for IF staining and microscopy was
a modified version of that used in our previous studies.6,7
The whole samples were fixed overnight with formalin,
and then they were washed by washing buffer (phosphate
buffered saline). The samples were postfixed and per-
meabilized with 100% methanol at e20C overnight.
Samples were then incubated in PBST (phosphate buffered
saline with 0.05% Triton) for 10 minutes. After washing, the
samples were incubated in 2 mg/ml proteinase K for 10
minutes at 37C. The samples were then incubated for 30
minutes in blocking buffer (phosphate buffered saline
containing 5% (wt/vol; BSA) to minimize nonspecific
binding. The samples were then incubated at 4C overnight
with the diluted primary antibodies (ZO-1 or occludin).
Following incubation, the samples were washed, and they
were then exposed to the respective secondary antibody
for 1 hour. Finally, the sections were covered by a slip
with mounting solution (Zymed, Carlton Ct., South San
Francisco, California, USA) before being viewed by confocal
laser scanning microscopy.
To determine and compare the localization of specific
proteins, IF-stained samples were observed with a confocal
laser-scanning microscope (Leica Lasertechnik, Heidelberg,
Germany). The 488-nm argoneion laser and the 543-nm
heliumeneon laser were used for observing the fluorescent
staining of Alexa Fluor 488 and Alexa Fluor 546, respec-
tively, to give the appropriate excitation wavelengths. The
micrographs taken from each photomultiplier were subse-
quently merged so that the different-colored labels could
be simultaneously visualized.
Statistical analysis
The difference between groups was analyzed by the Mann-
Whitney U-test using the SPSS 12.0 software (SPSS, Chicago,
IL, USA), and significance was established when p < 0.05.
Values are expressed as the means  standard error (SE).
Results
The decreased expressions of ZO-1 and occludin in the IC/
PBS group compared to the control group by immunoblot-
ting and IHC staining. The relative intensities of the ZO-1
and occludin were higher approximately 1.8- and 1.7-fold in
the control group than in the study group, respectively
(93.79  3.75 vs. 52.  4.25 and 103.23  7.51 vs.
60.20  6.10) These results are shown in Figs. 1 and 2. We
use the CK7 stain to identify the thickness of bladder uro-
thelial layer that revealed thicker and intact urothelium of
the control group, conversely, the bladder exhibited thin-
ning and denudation of urothelium in the study group
(Fig. 3A and D). IHC staining for ZO-1 and occludin showed
stronger immunoreactivity in the control group than in the
study group (Fig. 3B,C,E and F). By confocal microscopic
findings, the results of longitudinal micrographs showedthat the expression of ZO-1 and occludin were discontin-
uous distribution in bladder urothelium of the IC/PBS group
(Fig. 4). Moreover, the decreased tight junction proteins
expression causing thinning cell junction and interrupted
urothelial layer of the study group (Fig. 5A and B) compared
with the control group (Fig. 5D and E). The merged images
showed colocalization of ZO-1 and occludin in both groups
(Fig. 5C and F).
Figure 3 (AeC) Micrographs of representative sections of study; and (DeF) and control groups after CK7 (A and D), ZO-1 im-
munostaining (B and E), or occludin immunostaining (C and F). Black arrow: urothelium. Magnification: 400. ZO-1 Z zonula
occludens-1.
Figure 4 (AeC) Representative longitudinal micrographs of patients with study; and (DeF) control groups after double immu-
nofluorescent staining and confocal laser scanning microscopy for ZO-1 (red; A and D), occludin (green; B and E) and merged image
(C and F). Arrowhead: discontinuous. Magnification: 200. ZO-1 Z zonula occludens-1.
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Figure 5 (AeC) Representative horizontal micrographs of patients with study; and (DeF) control groups after double immuno-
fluorescent staining and confocal microscopy for ZO-1 (red; A and D), occludin (green; B and E) and merged images showed
colocalization of ZO-1 and occludin (C and F). Arrows: cell junction. Magnification: 1600. ZO-1 Z zonula occludens-1.
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The role of tight junctions is to allow urothelium to serve as
a barrier between urine and its solutes and the underlying
bladder.8,9 In IC/PBS, it has long been recognized as
a disease of the urothelial barrier dysfunction.8,10 The IC/
PBS bladder loses its normal impermeability (leaky epithe-
lium) combined with potassium diffusion into the bladder
wall that causes depolarization of sensory nerves and
muscles and injures tissue which lead the pelvic pain,
urgency, and frequency of urination.8,11,12 The urothelial
barrier function is supported by the structural integrity of
tight junctions. Tight junctions are the most apical junction
complexes, and they were recently shown to include ZO-1
and occludin (transmembrane protein) in the mammalian
bladder.13 The decreased expression of tight junction
proteins causing an increase of bladder urothelial perme-
ability that results in passage of small ions across the
bloodeurine barrier in patients with IC/PBS.
It has been hypothesized that potassium fulfills this role
because its levels in urine are quite high, ranging from
30e120 mEq/L.8,10 Conversely, the potassium concentra-
tion is only 3.5e4.5 mEq/L of serum in human. Such levels
not only depolarize nerves and muscles and cause tissue
injury,8,10 these may be also the reasons to lead clinical
symptoms when potassium leakage in IC/PBS patients.
Furthermore, it could increase potassium leakage due to
the combination of osmotic and increased hydrostatic
pressure.10 Simultaneously, to decrease blood perfusion
and exacerbates the urothelial defect causing more
significant symptoms when bladder distention in IC/PBS
patients.
Previous studies have reported that antiproliferative
factor is a small glycoprotein could inhibit cell growth then
decrease the expression of the tight junction proteinszonula occludens-1 and occludin causing an increase of
paracellular permeability in IC urothelium.13 Hauser et al.
have also reported that the loss of barrier function markers
in the IC urothelium.11 The loss of the glycosaminoglycan
layer was associated with abnormal expression of proteo-
glycan core proteins biglycan and perlecan on the luminal
layer. And the defects in the expression of perlecan
(located on the basal laminae) or syndecan (located on the
cell surface) in IC urothelium, may be reduced of critical
growth factors such as fibroblast growth factor-7 which
regulates the growth of urothelial cells or to affect down-
stream signaling by the receptor.11 Recent findings suggest
that the higher levels of cell apoptosis and abnormal
E-cadherin expression in the bladder urothelium of patients
with IC/PBS.14 These above mechanisms might decrease the
thickness of bladder urothelium as our findings then causing
an increase of urothelial permeability and associated with
patient’s clinical symptoms.
The establishment and maintenance of tight junctions
function are crucial to the bladder urothelium because its
defective integrity plays a role in the pathogenesis of IC/
PBS. Currently, some symptoms of IC/PBS patients would be
relieved by the oral pentosan polysulfate (Elmiron, Ivax
Pharmaceuticals, Miami, FL, U.S.A) or intravesical instilla-
tion of hyaluronic acid and liposome.9,15e18 Our findings
might provide the treatment mechanisms to repair the
discontinuous urothelium and to decrease the urothelial
permeability of patients following the above treatments.
Taken together, our data showed that decreased
expression of tight junction proteins (ZO-1 and occludin)
and interruption of bladder urothelium in IC/PBS patients
under confocal microscopy. These findings might provide
the basis of treatment mechanisms to repair the discon-
tinuous urothelium for relieving some clinical symptoms of
patients with IC/PBS.
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